Results 1 to 10 of about 3,079 (186)

Idarucizumab Reversal in Subdural Hemorrhage: A Single-Center Experience [PDF]

Life
Prompt reversal of anticoagulation in the elderly population with subdural hematoma (SDH) is critical to reduce morbidity and facilitate timely surgical intervention. In patients receiving dabigatran, idarucizumab provides rapid anticoagulation reversal.
Anita Mrvar Brečko, Monika Simerl Jožef, Ana Trebše, Matija Zupan, Tomaž Velnar, Senta Frol   +5 more
doaj   +5 more sources

Idarucizumab more effectively reverses the anticoagulant effects of dabigatran acylglucuronide than dabigatran [PDF]

Scientific Reports
Dabigatran acylglucuronide, an active metabolite of dabigatran, exhibits higher plasma concentrations and distinct anticoagulant effects compared to dabigatran, suggesting that it may play a more significant role in overall anticoagulant activity than ...
Jong-Min Kim, Young Yoon Bang, Kyoung-Ah Kim, Jin-Woo Park, Ji-Young Park   +4 more
doaj   +5 more sources

Idarucizumab for Emergency Reversal of the Anticoagulant Effects of Dabigatran: Final Results of a Japanese Postmarketing Surveillance Study [PDF]

Cardiology and Therapy, 2023
Introduction Idarucizumab, a monoclonal antibody fragment that rapidly reverses the anticoagulant effects of dabigatran, was approved in Japan in September 2016, at which time an all-case, postmarketing surveillance (PMS) study was initiated to collect ...
Masahiro Yasaka, Hiroyuki Yokota, Michiyasu Suzuki, Hidesaku Asakura, Teiichi Yamane, Yukako Ogi, Takaaki Kimoto, Daisuke Nakayama   +7 more
doaj   +3 more sources

Retrospective Observational Study of Patients With Subdural Hematoma Treated With Idarucizumab [PDF]

Neurotrauma Reports, 2023
Use of anticoagulants is increasing with the aging of societies. The safe first-line drug is likely to be a direct oral anticoagulant (DOAC), but outcomes of treatment of traumatic brain injury (TBI) with anticoagulants are uncertain.
Eiichi Suehiro, Hideyuki Ishihara, Yohei Kogeichi, Tsunenori Ozawa, Koichi Haraguchi, Masaru Honda, Yumie Honda, Makoto Inaba, Ryusuke Kabeya, Naoaki Kanda, Kenta Koketsu, Nobukuni Murakami, Hidetoshi Nakamoto, Kotaro Oshio, Kuniyasu Saigusa, Takashi Shuto, Shuichi Sugiyama, Kenji Suzuyama, Tsuguaki Terashima, Mitsuharu Tsuura, Mitsutoshi Nakada, Hitoshi Kobata, Toshio Higashi, Nobuyuki Sakai, Michiyasu Suzuki   +24 more
doaj   +3 more sources

Idarucizumab in dabigatran-treated patients with acute stroke: a review and clinical update [PDF]

Frontiers in Neurology
Idarucizumab is an antibody fragment specific for the immediate reversal of dabigatran anticoagulation effects. The use of idarucizumab is approved for dabigatran-treated patients suffering from life-threatening or uncontrolled bleeding and those in need
Senta Frol, Senta Frol, Janja Pretnar Oblak, Janja Pretnar Oblak, Mišo Šabovič, Mišo Šabovič, George Ntaios, Pawel Kermer, Pawel Kermer   +8 more
doaj   +3 more sources

Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Thrombolytic Therapy [PDF]

Medicina, 2022
Background and Objectives: Thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA) is used to treat acute ischemic stroke. Dabigatran is a reversible thrombin inhibitor approved for stroke prevention in patients with nonvalvular ...
Ilga Kikule, Alise Baborikina, Iveta Haritoncenko, Guntis Karelis   +3 more
doaj   +3 more sources

Practical use of idarucizumab

Кардиоваскулярная терапия и профилактика, 2023
The number of patients with indications for direct oral anticoagulants (DOACs) to prevent thrombotic events is steadily growing. However, in 1,1-2,2% of cases, ischemic strokes occur within DOAC therapy.
G. R. Ramazanov, E. A. Kovaleva, E. V. Klychnikova, S. S. Petrikov, N. A. Shamalov, I. S. Aliev, E. V. Shevchenko   +6 more
doaj   +3 more sources

Reversal of dabigatran and apixaban-induced coagulopathy using idarucizumab, fibrinogen, and prothrombin complex concentrate: A case report [PDF]

Heliyon
This case report examines the combined use of fibrinogen concentrate, four-factor prothrombin complex concentrate (PCC), and idarucizumab, a specific antidote for dabigatran, to reverse the anticoagulant effects of dabigatran and apixaban-induced ...
Elia Morando, Lorenzo Losso, Massimo Carollo, Ilaria Costantini, Matilde Bacchion, Lucia Drezza, Giorgio Ricci   +6 more
doaj   +3 more sources

Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report [PDF]

Journal of Medical Case Reports, 2019
Background Idarucizumab is a specific antidote for the anticoagulant dabigatran. Although its efficacy has been recently reported, the drug is still in postmarketing surveillance and requires case data in different emergency settings. A newer intravenous
Toshiyuki Ohtani, Ryosuke Sintoku, Tasuku Yajima, Naoyuki Kaneko   +3 more
doaj   +2 more sources

Idarucizumab as Antidote to Intracerebral Hemorrhage under Treatment with Dabigatran [PDF]

Case Reports in Neurology, 2016
Background and Purpose: Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of ...
Valentin Held, Philipp Eisele, Christoph C. Eschenfelder, Kristina Szabo   +3 more
doaj   +2 more sources